BioWorld MedTech
Archive Search

User ID

Password

Forgot password

Remember my login



New User ?

BioWorld MedTech Twitter

Clarivate Analytics

Today's Issue of BioWorld MedTech

Wednesday, January 24, 2018

Today's Headlines

JNJ continues turn around of device unit, sees 5.9 percent increase in sales for 4Q17

Johnson & Johnson Corp. brought in about $20.2 billion in sales for 4Q17, beating Wall Street consensus of $20.08 billion. One of the bright spots for Brunswick, N.J.-based Johnson & Johnson was the continued improvement of its medical device division. In 2017, J&J's device offerings increased in sales by about 8.3 percent and brought in about $7 billion. This exceeded analysts' consensus of $6.9 billion.

Boston Scientific becomes contender in DBS market with Vercise approval

Boston Scientific Corp. is entering into the deep brain stimulation (DBS) market in the U.S. with its latest FDA-approved technology. The Marlborough, Mass.-based company revealed on Monday that it has received approval for the Vercise deep brain stimulation system. News of the FDA-nod caused Boston Scientific (NYSE:BSX) shares to increase by 2 percent in after-hours trading Monday. The slight increase comes on the heels of a 7.5 percent drop in shares the company experienced in late November, when it said it would delay commercialization efforts of its Lotus Edge aortic valve system. (See BioWorld MedTech, Nov. 30, 2017.)

Edwards snags whale of a deal with its $250M Harpoon buy

Structural heart disease-focused device firm, Edwards Lifesciences Corp., has acquired privately held Harpoon Medical Inc., which specializes in mitral valve repair devices while the heart is beating. The agreement will begin with an initial cash payment of $100 million and up to $150 million in milestone payments over the next decade.


Home   |   About Us   |   Contact Us   |   Copyright Notices   |   Terms of Use   |   Privacy Statement

clarivate.com | BioWorld.com | bioworldmedtech.com